| |NOVEMBER 20249UK MHRA APPROVES SPARSENTAN FOR IGA NEPHROPATHY TREATMENTCHRONIC THERAPIES DRIVE 10 PERCENT GROWTH IN INDIAN PHARMA MARKETThe MHRA in the UK has given the approval to sparsentan (Filspari) for the treatment of IgAN. Berger's disease, or IgA neuropathy, is a kidney condition caused by the accumulation of immunoglobulin A (IgA) antibodies in the kidneys.Sparsentan was authorized through the International Recognition Procedure (IRP) via route B. The primary component in Filspari, sparsentan, functions by inhibiting the receptors for two hormones known as endothelin and angiotensin. Endothelin and angiotensin are involved in controlling kidney processes like inflammation that contribute to the advancement of kidney injury.By obstructing these receptors, Filspari reduces the protein leakage into the urine, thus aiding in the delay of disease progression. Vifor France was granted a new marketing authorization on November 6, 2024 through Route B of the International Recognition Procedure (IRP). The European Medicines Agency (EMA) served as the Reference Regulator (RR) with the procedure number (EMEA/H/C/005783/0000).The MHRA oversees the regulation of medicines and medical devices in the UK to ensure they are effective and safe for use. All of our efforts are supported by strong and evidence-based decisions to make sure the advantages outweigh any potential risks. The MHRA is a branch of the Department of Health and Social Care that operates as an executive agency. POLong-term health management products, specifically chronic therapies, have been driving the growth of the Indian Pharmaceutical Market (IPM) with a 10percent increase, in contrast to acute therapies which saw a 2percent growth, showing a trend towards prolonged health care solutions. Strong innovation and introducing new products in the industry also helped drive growth.The Total Sales Audit (TSA) and Secondary Sales Audit (SSA) numbers indicate the market is consistently growing. TSA for the fiscal year ending in October 2024 amounted to Rs 226,217 Cr, showing a 6.8percent increase, while SSA was at Rs 190,940 Cr, with a growth rate of 6.7percent. During October, TSA was worth Rs 19,957 Cr, showing a 5.0percent growth, while SSA was valued at Rs 16,843 Cr, indicating a 4.5percent rise from the previous year.Medical fields like cardiovascular care and diabetes treatment played a significant role in driving the market's growth. The use of medications such as Sacubitril + Valsartan provided a boost to cardiac care, showing notable progress. Similarly, the sales of Glimepiride + Metformin in the anti-diabetic sector amounted to Rs 291 Cr. Gastrointestinal treatments also did well, with Esomeprazole + Domperidone experiencing a significant increase of 29percent. Conversely, most subcategories of respiratory and pain therapies experienced decreases, except for certain combinations like Formoterol + Budesonide, which remained stable.Leading brands demonstrated remarkable increases in sales. Foracort maintained its top spot, starting with Rs 75 Cr in October 2024. Pan-D had a remarkable 20percent growth, solidifying its position in the top 10, while Influvac saw an impressive 89percent growth, moving up 29 spots. PO
< Page 8 | Page 10 >